China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's largest private integrated healthcare company Shanghai Fosun Pharmaceutical Co. Ltd. will focus on gaining more market share in China with its branded generic business and branded traditional Chinese medicines, the company said during China's first ever Biotechnology Industry Organization conference held in Shanghai
You may also be interested in...
Shanghai Fosun And Chindex CEO Team Up To Capitalize On China’s Growing Private Markets
As China opens up its private hospital market and a new wave of investment, major players such as Chindex International Inc. are reevaluating and repositioning themselves to benefit from the growing private infrastructure.
Lonza Forms JV With Shanghai Fosun To Tap Chinese Generics Market
Swiss firm Lonza Group AG, a global supplier of active pharmaceutical ingredients has announced a joint venture with Shanghai Fosun Pharmaceutical. The 50/50 JV will develop and launch a portfolio of generic products in China
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership